Case Study: a leading RNAi therapeutics company cuts Pre-IND reporting time 4X with Elucidata’s Polly Platform

Leading RNAi Therapeutics Company cuts regulatory reporting time by 4X with Elucidata

The customer, a leading RNAi therapeutics company, faced the challenge of manually generating Pre-IND safety dossiers, a time-consuming process that hindered its ability to scale its pipeline. To address this, they partnered with vendor Elucidata to leverage the Polly Platform and its generative AI capabilities.

Elucidata implemented custom agentic AI workflows on its Polly Platform to automate literature curation and scientific summarization. This solution slashed regulatory reporting time by 4X, from 160 to 40 hours per molecule, while achieving 96% factual accuracy. This enabled the customer to support over 20 active therapeutic programs without adding staff, demonstrating significant efficiency gains and cost savings.